Principal Financial Data
(millions of yen)
|Net income attributable to owners of the parent||11,749||12,953||16,302||16,866||20,702||21,000|
|Depreciation and amortization||2,648||2,773||3,418||3,468||3,550||3,800|
In FY 2020, Nippon Shinyaku’s business performance continued to be affected by the COVID-19 pandemic in its domestic Pharmaceuticals and Functional Food segments. Nevertheless, net sales increased mainly thanks to the royalties from the overseas sales of Uptravi, Nippon Shinyaku’s originally developed treatment drug for pulmonary arterial hypertension, the growth of a range of new pharmaceuticals launched in Japan, and milestone income from Uptravi.
Net income attributable to owners of the parent
The operating income was 26,134 million yen, 20.6% up from the previous term, and the net income attributable to owners of the parent 20,702 million yen, 22.7% up from the previous term, mainly due to increased sales and a lower cost to sales ratio resulting from the composition of sales items.
Principal Financial Indicators
|Fiscal year (yen)||2017/3||2018/3||2019/3||2020/3||2021/3|
|Earnings per share (EPS)||174.42||192.31||242.04||250.42||307.37|
|Dividend per share||48||52||70||86||99|
|Return on equity (ROE)||10.8||10.8||12.5||12.0||13.5|
EPS / ROE
- Earnings per share (EPS)
- Return on equity (ROE)
Dividend per share / Payout ratio
- Dividend per share
- Payout ratio
|Fiscal year (millions of yen)||2017/3||2018/3||2019/3||2020/3||2021/3|
|Cash flow from operating activities||18,916||6,719||15,310||12,737||21,388|
|Cash flow from investing activities||-5,750||-11,342||511||-2,339||-1,564|
|Cash flow from financing activities||-2,193||-3,787||-3,708||-5,660||-6,199|
Long-term Chronological Data
View long-term chronological data from here.